Raleigh, NC (PRWEB) March 11, 2011
Agile Sciences has been awarded a $75,000 grant from the Cystic Fibrosis Foundation which will facilitate testing of the company’s lead pharmaceutical compounds toward bacterial isolates from cystic fibrosis patients. The company will collaborate with a leading cystic fibrosis expert and expects to complete the initial assessment during 2011.
Cystic fibrosis patients are particularly susceptible to infection of the lung by bacteria. The persistence of chronic infection even with antibiotic therapy has been linked, in part, to bacteria’s ability to form complex communities called biofilms. Agile Sciences’ technology inhibits the formation of biofilms and also disperses existing biofilms.
Agile Sciences’ co-founder, Dr. John Cavanagh, commented, “We are eager to test our compounds toward biofilms formed from Pseudomonas aeruginosa bacteria isolated from the lungs of cystic fibrosis patients, and we are very grateful to the Cystic Fibrosis Foundation for the funding that will allow us to complete this initial assessment.”
Project Principal Investigator, Dr. Laura Guogas, stated: “We are excited to see if we can duplicate our in vitro results demonstrating dispersion of laboratory P. aeruginosa biofilms with clinical isolates of this species because P. aeruginosa is the most prevalent bacterium isolated from advanced cases of lung infection in cystic fibrosis patients.”
About Agile Sciences:
Agile Sciences is headquartered on North Carolina State University's Centennial Campus. The company was founded in 2007 by Professors Christian Melander and John Cavanagh of North Carolina State University (NCSU) to provide commercial solutions to those industries plagued by the effects of biofilms. The company's proprietary compounds are derived from the Agelas conifera sea sponge and have been shown to be effective in dispersing biofilms. For additional information, please visit http://www.agilesci.com.
About the Cystic Fibrosis Foundation:
The Cystic Fibrosis Foundation is the world’s leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, please visit http://www.cff.org.
# # #